P Escribano-Subías1, R Del Pozo2, A Román-Broto3, J A Domingo Morera4, A Lara-Padrón5, T Elías Hernández6, L Molina-Ferragut7, I Blanco8, J Cortina9, J A Barberà10. 1. Pulmonary Hypertension Unit, RIC group, Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: pilar.escribano.subias@gmail.com. 2. Pulmonary Hypertension Unit, Pneumonology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. 3. Department of Pneumonology, Hospital Universitari Vall d´Hebrón, Universitat Autonoma, Barcelona, Spain; Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Spain. 4. Department of Pneumonology, Hospital Universitario Miguel Servet, Zaragoza, Spain. 5. Department of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. 6. Department of Pneumonology, Hospital Universitario Virgen del Rocío, Sevilla, Spain. 7. Department of Cardiology, Hospital del Mar, Barcelona, Spain; Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 8. Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Spain; Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Spain. 9. Pulmonary Hypertension Unit, Cardiac Surgery Department, Hospital Universitario 12 de Octubre, Madrid, Spain. 10. Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Spain; Department of Pulmonary Medicine, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: The Spanish "Registry of Pulmonary Arterial Hypertension" (REHAP), started in 2007, includes chronic thromboembolic hypertension (CTEPH) patients. Based on data provided by this registry and retrospective data from patients diagnosed during 2006 (≤ 12 months since the registry was created), clinical management and long-term outcomes of CTEPH patients are analyzed nationwide for the first time in a scenario of a decentralized organization model of CTEPH management. METHODS AND RESULTS: A total of 391 patients (median [Q1:Q3] age 63.7 [48.0;73.3] years, 58% females) with CTEPH included during the period January 1, 2006-December 31, 2013 in the REHAP registry were analyzed. Rate of pulmonary endarterectomy (PEA) was 31.2%, and highly asymmetric among centers: rate was 47.9% at two centers designated as CTEPH expert centers, while it was 4.6% in other centers. Among patients not undergoing PEA, 82% were treated with therapies licensed for pulmonary arterial hypertension (PAH). Five-year survival rate was 86.3% for PEA patients, and 64.9% for non-PEA patients. Among non-PEA patients, presenting proximal lesions (42% of non-referred patients) was associated with a 3-fold increase in mortality. PEA patients achieved significantly better hemodynamic and clinical outcomes at one-year follow-up compared to non-PEA patients. Patients not being referred for PEA assessment were older and had a worse functional capacity. Older age was the most deterrent factor for non-operability. CONCLUSION: Despite the increase in diagnosis and expertise in PEA-specialized centers, an important percentage of patients do not benefit of PEA in a decentralized organization model of CTEPH management.
BACKGROUND: The Spanish "Registry of Pulmonary Arterial Hypertension" (REHAP), started in 2007, includes chronic thromboembolic hypertension (CTEPH) patients. Based on data provided by this registry and retrospective data from patients diagnosed during 2006 (≤ 12 months since the registry was created), clinical management and long-term outcomes of CTEPHpatients are analyzed nationwide for the first time in a scenario of a decentralized organization model of CTEPH management. METHODS AND RESULTS: A total of 391 patients (median [Q1:Q3] age 63.7 [48.0;73.3] years, 58% females) with CTEPH included during the period January 1, 2006-December 31, 2013 in the REHAP registry were analyzed. Rate of pulmonary endarterectomy (PEA) was 31.2%, and highly asymmetric among centers: rate was 47.9% at two centers designated as CTEPH expert centers, while it was 4.6% in other centers. Among patients not undergoing PEA, 82% were treated with therapies licensed for pulmonary arterial hypertension (PAH). Five-year survival rate was 86.3% for PEA patients, and 64.9% for non-PEA patients. Among non-PEA patients, presenting proximal lesions (42% of non-referred patients) was associated with a 3-fold increase in mortality. PEA patients achieved significantly better hemodynamic and clinical outcomes at one-year follow-up compared to non-PEA patients. Patients not being referred for PEA assessment were older and had a worse functional capacity. Older age was the most deterrent factor for non-operability. CONCLUSION: Despite the increase in diagnosis and expertise in PEA-specialized centers, an important percentage of patients do not benefit of PEA in a decentralized organization model of CTEPH management.
Authors: John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte Journal: Ann Cardiothorac Surg Date: 2022-03
Authors: Abdullah M Aldalaan; Sarfraz A Saleemi; Ihab Weheba; Abeer Abdelsayed; Pekka Hämmäinen; Maha M Aleid; Fatima Alzubi; Hamdeia Zaytoun; Nadeen Alharbi Journal: ERJ Open Res Date: 2020-05-11
Authors: Grzegorz Kopeć; Olga Dzikowska-Diduch; Ewa Mroczek; Tatiana Mularek-Kubzdela; Łukasz Chrzanowski; Ilona Skoczylas; Michał Tomaszewski; Małgorzata Peregud-Pogorzelska; Danuta Karasek; Ewa Lewicka; Wojciech Jacheć; Zbigniew Gąsior; Piotr Błaszczak; Katarzyna Ptaszyńska-Kopczyńska; Katarzyna Mizia-Stec; Andrzej Biederman; Dariusz Zieliński; Roman Przybylski; Piotr Kędzierski; Marcin Waligóra; Marek Roik; Marek Grabka; Joanna Orłowska; Aleksander Araszkiewicz; Marta Banaszkiewicz; Sylwia Sławek-Szmyt; Szymon Darocha; Wojciech Magoń; Alicja Dąbrowska-Kugacka; Jakub Stępniewski; Kamil Jonas; Karol Kamiński; Jarosław D Kasprzak; Piotr Podolec; Piotr Pruszczyk; Adam Torbicki; Marcin Kurzyna Journal: Ther Adv Chronic Dis Date: 2021-03-25 Impact factor: 5.091
Authors: Yousef Shahin; Samer Alabed; Syed Rehan Quadery; Robert A Lewis; Christopher Johns; Dheyaa Alkhanfar; Maria Sukhanenko; Faisal Alandejani; Pankaj Garg; Charlie A Elliot; Abdul Hameed; Athaniosis Charalampopoulos; James M Wild; Robin Condliffe; Andrew J Swift; David G Kiely Journal: Front Med (Lausanne) Date: 2022-03-14
Authors: Syed Rehan Quadery; Andrew J Swift; Catherine G Billings; Alfred A R Thompson; Charles A Elliot; Judith Hurdman; Athanasios Charalampopoulos; Ian Sabroe; Iain J Armstrong; Neil Hamilton; Paul Sephton; Sian Garrad; Joanna Pepke-Zaba; David P Jenkins; Nicholas Screaton; Alexander M Rothman; Allan Lawrie; Trevor Cleveland; Steven Thomas; Smitha Rajaram; Catherine Hill; Christine Davies; Christopher S Johns; Jim M Wild; Robin Condliffe; David G Kiely Journal: Eur Respir J Date: 2018-09-16 Impact factor: 33.795